…
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1511.43M | 1056.93M | 1033.02M | 1220.00M | 1572.00M |
| Minority interest | -212.90M | -202.96M | -233.46M | -222.00M | -250.00M |
| Net income | 977.63M | 537.91M | 499.00M | 673.00M | 969.00M |
| Selling general administrative | 3032.73M | 2366.29M | 2388.38M | 3784.00M | 3096.00M |
| Selling and marketing expenses | - | 776.53M | 807.96M | - | - |
| Gross profit | 5027.12M | 4756.65M | 4925.01M | 5310.00M | 5077.00M |
| Reconciled depreciation | 1500.41M | 1742.26M | 1751.97M | 1838.36M | 1623.68M |
| Ebit | 1896.29M | 1463.97M | 1457.65M | 1576.10M | 1845.85M |
| Ebitda | 3395.73M | 3206.23M | 3209.63M | 1580.00M | 1925.00M |
| Depreciation and amortization | 1499.44M | 1742.26M | 1751.97M | - | - |
| Operating income | 1837.31M | 1392.39M | 1369.44M | 1297.00M | 1760.00M |
| Other operating expenses | 17783.34M | 17943.51M | 18084.18M | - | - |
| Interest expense | 384.86M | 407.04M | 424.64M | 360.00M | 353.60M |
| Tax provision | 320.97M | 316.06M | 300.56M | 325.00M | 353.00M |
| Interest income | 69.61M | 71.58M | 88.22M | 68.00M | 73.00M |
| Net interest income | -314.80M | -335.47M | -336.42M | -292.00M | -280.00M |
| Income tax expense | 320.88M | 316.06M | 300.56M | 324.95M | 352.83M |
| Total revenue | 19620.65M | 19335.91M | 19453.62M | 19398.00M | 17619.00M |
| Total operating expenses | 3189.80M | 3364.26M | 3555.57M | 18101.00M | 15859.00M |
| Cost of revenue | 14593.53M | 14579.26M | 14528.61M | 14088.00M | 12542.00M |
| Total other income expense net | -325.88M | -335.47M | -336.42M | 215.00M | 92.00M |
| Net income from continuing ops | 1191.27M | 740.87M | 732.46M | 895.00M | 1219.00M |
| Net income applicable to common shares | - | - | - | 673.40M | 969.31M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 30990.39M | 33566.58M | 33929.81M | 35754.00M | 34367.00M |
| Intangible assets | 1254.02M | 1370.08M | 1362.33M | 1518.68M | 1459.39M |
| Other current assets | 888.02M | 487.38M | 1326.39M | 370.83M | 346.31M |
| Total liab | 16712.74M | 17798.07M | 19103.27M | 20305.00M | 20388.00M |
| Total stockholder equity | 13304.85M | 14576.56M | 13620.26M | 15449.00M | 13979.00M |
| Other current liab | 3308.43M | 3092.67M | 3370.28M | 2329.67M | 2552.96M |
| Common stock | 293.30M | 293.41M | 293.41M | 293.41M | 293.00M |
| Capital stock | 293.41M | 293.41M | 293.41M | 293.41M | 293.00M |
| Retained earnings | 12203.34M | 11266.29M | 10921.69M | 10711.71M | 10826.14M |
| Other liab | - | - | - | 2661.95M | 2395.14M |
| Good will | 13566.31M | 15170.65M | 14650.01M | 15791.18M | 14361.58M |
| Other assets | - | - | -0.00M | 1127.27M | 1239.97M |
| Cash | 1598.40M | 1150.95M | 1377.03M | 1273.79M | 1481.65M |
| Total current liabilities | 6242.66M | 5660.06M | 6111.59M | 6467.31M | 7257.63M |
| Current deferred revenue | - | 82.17M | 85.82M | - | - |
| Net debt | 12098.49M | 9827.96M | 10673.39M | 7260.02M | 8571.00M |
| Short term debt | 2196.51M | 1218.27M | 1561.56M | - | - |
| Short long term debt | 1613.04M | 577.38M | 944.60M | 1363.08M | 1924.00M |
| Short long term debt total | 13696.89M | 10978.91M | 12050.41M | - | - |
| Other stockholder equity | 2492.34M | 3345.41M | 3380.33M | -388.47M | -1311.64M |
| Property plant equipment | - | - | - | 8339.81M | 8551.47M |
| Total current assets | 7895.04M | 7922.74M | 8701.41M | 8203.45M | 7967.24M |
| Long term investments | 1323.48M | 1416.69M | 1254.51M | 773.72M | 786.90M |
| Net tangible assets | - | - | - | -3320.41M | -3122.19M |
| Short term investments | 127.49M | 295.63M | 136.29M | 169.98M | 136.36M |
| Net receivables | 3140.82M | 3920.87M | 3637.99M | 4031.60M | 3906.68M |
| Long term debt | 5691.85M | 6260.82M | 6959.86M | 7170.73M | 6647.00M |
| Inventory | 2140.20M | 2067.92M | 2179.18M | 2296.21M | 2038.01M |
| Accounts payable | 737.72M | 984.32M | 762.07M | 892.64M | 818.51M |
| Accumulated other comprehensive income | -1684.14M | -328.55M | -975.17M | - | - |
| Non currrent assets other | 3767.38M | 198.32M | 223.58M | 6054.00M | 6263.00M |
| Non current assets total | 23095.35M | 25643.83M | 25228.40M | 27551.00M | 26400.00M |
| Capital lease obligations | 3490.71M | 4140.70M | 4145.95M | 4678.76M | 4749.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -4.02M | -84.94M | -544.23M | -71.28M | -61.58M |
| Change to liabilities | - | - | - | -356.79M | -363.95M |
| Total cashflows from investing activities | -693.29M | -84.94M | -544.23M | -734.73M | -1196.23M |
| Net borrowings | 149.58M | -1905.15M | -1189.79M | -1023.04M | -358.90M |
| Total cash from financing activities | -1431.65M | -2569.30M | -1858.53M | -1617.36M | -1024.38M |
| Change to operating activities | - | - | - | 154.03M | 164.20M |
| Net income | 978.00M | 740.87M | 732.46M | 673.40M | 969.31M |
| Change in cash | 558.68M | -241.90M | 153.44M | -207.87M | 400.12M |
| Begin period cash flow | 1039.83M | 1427.22M | 1273.79M | 1481.65M | 1081.54M |
| End period cash flow | 1598.51M | 1185.33M | 1427.22M | 1273.79M | 1481.65M |
| Total cash from operating activities | 2679.99M | 2386.14M | 2628.80M | 2167.38M | 2489.50M |
| Depreciation | 1462.86M | 1742.26M | 1751.97M | 1658.28M | 1535.58M |
| Other cashflows from investing activities | - | 14.10M | 16.14M | - | - |
| Dividends paid | 422.36M | 349.16M | 328.62M | -395.56M | -392.45M |
| Change to inventory | -248.56M | 107.90M | -13.14M | -204.31M | -48.53M |
| Change to account receivables | -69.04M | -73.48M | -151.84M | -46.68M | -163.20M |
| Sale purchase of stock | -585.07M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | -1222.55M | -314.99M | -340.11M | -218.91M | -279.54M |
| Change to netincome | - | - | - | -98.09M | 32.59M |
| Capital expenditures | 915.03M | 699.36M | 684.60M | 723.99M | 854.36M |
| Change in working capital | 138.19M | 444.31M | 561.28M | -566.00M | -354.00M |
| Stock based compensation | - | - | 32.52M | - | 0.00M |
| Other non cash items | 128.15M | -468.62M | -327.27M | 1838.00M | 1624.00M |
| Free cash flow | 1764.97M | 1686.79M | 1944.20M | 756.00M | 806.00M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FMCQF Fresenius Medical Care AG & Co. KGaA |
- -% |
43.82 | 14.21 | 9.00 | 0.78 | 0.77 | 0.98 | 5.67 |
| HCA HCA Healthcare, Inc. |
-3.22 0.63% |
507.48 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-5.88 2.01% |
286.37 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.12 0.83% |
14.53 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
4.81 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Else-Kröner-Strasse 1, Bad Homburg, Germany, 61352
49 6172 609 0
109698
| Name | Title | Year Born |
|---|---|---|
| Ms. Helen Giza | CEO, Chief Transformation Officer, Acting CFO & Chair of Mgmt Board of Fresenius Med. Care Mgmt AG | 1968 |
| Mr. Robert Maurice Powell Jr. | Member of the Management Board of Fresenius Medical Care Management AG | 1955 |
| Dr. Franklin W. Maddux F.A.C.P. | Global Chief Medical Officer & Member of Management Board of Fresenius Medical Care Management AG | 1957 |
| Mr. William J. Valle | Management Board Member for Care Delivery of Fresenius Medical Care Management AG | 1960 |
| Dr. Katarzyna Mazur-Hofsab Ph.D. | Management Board Member for Care Enablement of Fresenius Medical Care Management AG | 1963 |
| Mr. Roberto Fuste | Exec. Advisor for Regional Strategy | 1952 |
| Dr. Nwamaka Eneanya M.D. | Head of Strategy & Operations | NA |
| Dr. Dominik Heger | Exec. VP and Head of Investor Relations, Strategic Devel. & Communications | NA |
| Mr. Borries Von Muller | Sr. VP of Global HR Employee Communications | 1961 |
| Mr. Joachim Weith | Sr. VP of Corp. Communications & Gov.al Affairs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.